DCR

mNSCLC - L1 - all population metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - all population

versus placebo plus SoC
sintillimab plus SoC vs. placebo plus SoC 1 -
versus Standard of Care (SoC)
cemiplimab vs. Standard of Care (SoC) 1 -
durvalumab alone vs. Standard of Care (SoC) 1 -
durvalumab plus tremelimumab vs. Standard of Care (SoC) 1 -
nivolumab plus ipilimumab plus SoC vs. Standard of Care (SoC) 1 -